Cynapsus arranges debenture financing

Cynapsus Therapeutics (TSX-V:CTH) has arranged a financing of $229,885 of 10% of secured Series E-4 debentures due Dec. 30, 2012. As part of the financing, the company will pay a 13% capital discount to the debenture holders, resulting in net proceeds to Cynapsus of $200,000 and issue 800,000 common shares to the debenture holders at [...]

Season’s Greetings (and JPM)

Dear Readers, Wow!  What an interesting year 2011 turned out to be. The BioTuesdays.com team – Len, Maria, Jen, Suh, Shelly, Greg and I – would like to wish you all a safe and happy holiday season.  We are taking a short break to spend time with family and friends. But, we will be back [...]

Cynapsus closes Adagio acquisition

Cynapsus Therapeutics (TSX-V:CTH) has completed the acquisition of Adagio Pharmaceuticals in a share exchange, terminating a license option agreement for the intellectual property owned by Adagio concerning the APL-130277 patent rights and know-how. “Cynapsus is focused on advancing our Parkinson’s drug candidate, APL-130277, and the original patent rights and know how held by Adagio are [...]

Cipher gets complete response for amended NDA

Cipher Pharmaceuticals’ (TSX:DND) amendment to its New Drug Application for CIP-Isotretinoin, a novel, patented formulation of the acne medication isotretinoin, has been accepted by the FDA as a complete, class 2 response. The FDA’s goal date under the Prescription Drug User Fee Act (PDUFA) is May 29, 2012. Cipher will receive a $1 million milestone [...]

JMP starts Novadaq at market outperform

JMP Securities has initiated coverage of Novadaq Technologies (TSX:NDQ) with an “outperform” rating and 12-month price target of $7. The stock closed at $4.72 on Monday SPY is a breakthrough imaging system that allows surgeons to visualize blood flow and perfusion in real-time. The company has established partnerships with LifeCell and Intuitive Surgical, which “in [...]

Diamedica humanizes Type 2 diabetes monoclonal antibody

Diamedica (TSX:DMA) has humanized its monoclonal antibody, DM-204, for Type 2 diabetes and diabetic-related complications of hypertension and cholesterol. The humanized DM-204 mAb demonstrated improved binding affinity of up to two orders of magnitude, compared with the recently announced first-generation mouse antibody. The increased binding affinity demonstrated by DM-204 has resulted in a significant improvement in [...]

Northwest Biotherapeutics nearing inflection point

After 15 years of research and clinical testing, Northwest Biotherapeutics (OTCBB:NWBO) is nearing an inflection point in its development of an immunotherapeutic cancer vaccine. “We are entering the home stretch in testing our lead program for the most lethal form of brain cancer, which should reach its primary endpoint in the neighborhood of 18 months,” [...]

Donald Wyatt joins Isotechnika board

Donald Wyatt, the founder of consultancy The Wyatt Group, has been appointed a director of Isotechnika Pharma (TSX:ISA), serving as a representative of 3SBio (NASDAQ:SSRX), a Chinese biotech company. Mr. Wyatt is currently an advisor to 3SBio. He replaces Dr. David Chen, COO of 3SBio, who recently has taken on additional responsibilities that make it [...]

Roth figures Somaxon parts worth more than the whole

Roth Capital Partners says that while the timing of Somaxon Pharmaceuticals’ (NASDAQ:SOMX) decision to seek strategic alternatives is not opportune; it could create value above the currently depressed stock price. Analyst Scott Henry figures Somaxon’s approved insomnia pill, Silenor, has a run rate of $15 million to $20 million in annual revenues. “We guess that [...]

Northwest Biotherapeutics refutes patent assertions

After obtaining confirmatory opinions from multiple experts in patent law, Northwest Biotherapeutics (OTCBB: NWBO) has reaffirmed that its lead program, applying DCVax-L for the treatment of brain cancer, continues to have “clear freedom to operate” in spite of U.S. patent 7,939,090 (the 090 patent) recently issued to Cedars Sinai, and licensed to Immunocellular Therapeutics (NASDAQ:IMUC). [...]

Next Page »